MedTrace Logo

Acrylamide and Health Outcomes

NCT06224725 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1700

Last updated 2025-03-06

No results posted yet for this study

Summary

Acrylamide, a widespread food-processing contaminant, poses a major public health concern due to its high exposure level in the general population and its toxicity. While animal evidence shows that acrylamide causes neurological alterations and may play a role in cardiovascular disease, evidence in humans is lacking. Our project aims to investigate whether dietary acrylamide exposure, measured in blood, increases the risk of dementia, Alzheimer's and Parkinson's diseases and myocardial infarction. In addition, the aim is to improve the understanding of the biological mechanisms underlying these associations integrating small compounds in blood (i.e., OMICS).

In two population-based cohorts, the Cohort of 60-Year-Olds and the Swedish Mammography Cohort, acrylamide will be assessed in blood samples using a case-cohort design (around 2145 individuals, 20-year follow-up). The results will be presented in four scientific publications using adequate data analysis. The project will run from 2024-2028.

The project´s findings will help improve public health through safer food and better nutrition. If findings indicate that acrylamide increases the risk of these diseases, this will urge interventions to decrease acrylamide exposure via food production and consumption. In turn, this will help to reduce the burden of these diseases. Even findings showing null association will be equally relevant to avoid unnecessary and costly preventive measures.

Conditions

Interventions

OTHER

dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)

Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.

Sponsors & Collaborators

Principal Investigators

  • Federica Laguzzi · Karolinska Instittutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06224725 on ClinicalTrials.gov